louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05150665: Evaluation of Mini and Macro-esthetics Following En- Masse Retraction Versus Two Step Retraction
Official title: Evaluation of Mini and Macro-esthetics Following En- Masse Retraction Versus Two Step Retraction in Maxillary Protrusion Cases: A Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Bimaxillary Protrusion
Keywords: Mini-esthetics
Macro-esthetics
En-masse Retraction
Two step retraction
Extra-oral photographs
Adobe photoshop CC 2017 software
Lateral Cephalometric Radiographs
Lead sponsor: Future University in Egypt
Sponsor class: OTHER
First posted: 2021-12-09
Enrollment: 30
Sex: ALL
Minimum age (years): 16
Maximum age (years): 24
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: There's a scarcity in literature concerning mini-esthetics specially maxillary gingival display changes following en-masse retraction and two-step retraction. The purpose of this study is to determine, In orthodontic patients with maxillary protrusion, which technique of retraction will result in better esthetics upon smiling following en-masse retraction or two step retraction mechanics.

Detailed description: This study will be conducted in order to evaluate which technique of retraction will provide better outcome regarding mini and macro esthetics. In terms of mini esthetics, posed smiles will be analyzed to evaluate maxillary gingival display, as well as the analysis of smile arc, buccal corridor, inter-labial gap. In terms of macro esthetics, frontal and profile poses will be assessed to evaluate the nasolabial angle, mentolabial angle and upper and lower lip protrusion/ E- plane.

Eligibility criteria: Inclusion Criteria:

* Adults and Adolescent patients (both genders)
* Age range (16-24)
* Patients with maxillary protrusion requiring first premolars extraction (Bimaxillary Protrusion or Class II division 1 cases).
* Patients with fully erupted permanent teeth (not necessarily including the third molar).
* Cases requiring maximum anchorage during retraction.
* Good general and oral health

Exclusion Criteria:

* Patients suffering from any neural disorders or systemic diseases interfering with tooth movement.
* Patients with soft tissue problems such as cleft-palate patients
* Patients with extracted or missing permanent teeth. (except for third molars).
* Patients with badly decayed teeth.
* Patients with any parafunctional habits (i.e. Bruxism, tongue thrusting, mouth breathing, etc....).
* Patients with previous orthodontic treatment.

Primary outcomes:
measure: Mini-esthetics including
timeFrame: From pre to post retraction (an average of 6 - 8 months)]
Secondary outcomes:
measure: Macro-esthetics evaluation of profile photograph including
timeFrame: upto 6 months from the start of orthodontic treatment.
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Future University In Egypt
Study officials:
affiliation: Future University in Egypt
name: Yehya mostafa, Professor and chairman
role: STUDY_DIRECTOR
References:
Clinical trial NCT02532465: Glottic View Using Supraglottic Devices in Pediatric Patients
Official title: Glottic View Using Supraglottic Devices in Pediatric Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Operative Surgical Procedures
Lead sponsor: Nationwide Children's Hospital
Sponsor class: OTHER
First posted: 2015-08-25
Enrollment: 50
Sex: ALL
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: Endotracheal intubation is the gold standard for securing the airway. However, while managing patients with difficult airways, various supraglottic devices have been used as rescue airway devices. The aim of this study is to compare the fiberoptic view through the internal aspect of the i-gel versus the Air-Q LMA in pediatric patients. By examining the fiberoptic view through these two devices, the investigators will determine which device provides a clearer passage to the glottic opening and is therefore the preferred conduit to aid endotracheal intubation in difficult airways.


Eligibility criteria: Inclusion Criteria:

* Patients less than 18 years of age who will be receiving an LMA as part of standard of care for their procedure.

Exclusion Criteria:

* None

Primary outcomes:
measure: Acceptable View of the Glottic Aperature (Grade I-II)
timeFrame: 15 seconds after insertion of Air-Q or i-gel
Secondary outcomes:
measure: Airway Insertion Time
timeFrame: Immediately after anesthesia induction
measure: Time to Achieve Best Fiberoptic View
timeFrame: 15 seconds after insertion of Air-Q or i-gel
Other outcomes:
Locations:
city: Columbus
country: United States
facility: Nationwide Children's
state: Ohio
Study officials:
References:
Clinical trial NCT02154165: Comparison Between Turquoise and Blue Light in Treatment of Neonatal Jaundice Using Light Emission Diodes
Official title: Comparison Between Turquoise and Blue Light in Treatment of Neonatal Jaundice Using Light Emission Diodes
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Uncomplicated Neonatal Hyperbilirubinemia
Keywords: Neonatal hyperbilirubinemia
Phototherapy
Light emitting diodes
Blue light
Turquoise light
Lead sponsor: University of Aarhus
Sponsor class: OTHER
First posted: 2014-06-03
Enrollment: 90
Sex: ALL
Minimum age (years): 33
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The optimal wavelength for phototherapy for neonatal jaundice remains to be clarified by clinical studies. Previous iv vivo studies have shown that turquoise light at wavelength about 490 nm is more efficacious than blue light at wavelength 460 nm, which is the golden standard in phototherapy treatment today. Though, previous studies used light tubes, today we use light emitting diodes (LED'S).

The overall aim of this study was therefore to compare the efficacy of turquoise LED's versus blue LED's for decreasing total serum bilirubin in neonates with gestational age \> 33 weeks and uncomplicated hyperbilirubinemia.


Eligibility criteria: Inclusion Criteria:

* Newborns with gestational age \>33 weeks and neonatal hyperbilirubinemia requiring treatment with phototherapy according to the national guidelines

Exclusion Criteria:

* Haemolytic disease (Rhesus and Kell blood type isoimmunization, spherocytosis)
* Liver disease

Primary outcomes:
measure: Decrease in total serum bilirubin
timeFrame: 24 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Aalborg
country: Denmark
facility: Neonatal department, Aalborg University Hospital
Study officials:
References:
Clinical trial NCT05447065: Impact of Vitamin D Supplementation on COVID-19 Vaccine Response and IgG Antibodies in Deficient Women.
Official title: Impact of Vitamin D Supplementation on COVID-19 Vaccine Response and IgG Antibodies in Deficient Women.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: COVID-19 Pandemic
D Vitamin Deficiency
Antibody Hypersensitivity
Keywords: COVID-19 Vaccine
Antibody
IgG
D vitamin
Nutrition
Lead sponsor: Ege University
Sponsor class: OTHER
Collaborators: name: Avrasya University
First posted: 2022-07-07
Enrollment: 33
Sex: FEMALE
Minimum age (years): 19
Maximum age (years): 23
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: Decreased immunity in individuals causes a decrease in vaccine response, and vitamin D worsens this course. Vitamin D is thought to be a vitamin that can strengthen the innate immune response, inhibit the adaptive system, and modulate the vaccine response.

The effect of vitamin D intake on antibodies was studied.


Eligibility criteria: Inclusion Criteria:

* The study consisted of young volunteer women who completed 2 doses of COVID-19 vaccines, did not receive the 3rd dose, and spent an average of 65 days over the 2nd dose. Participants were included in the study when IgM value was negative, IgG value was positive, they were not older than 25 years, and serum 25-Hydroxy (25(OH)) vitamin D was below 30 ng/mL.

Exclusion Criteria:

* In addition, individuals participating in the research who were pregnant, had physician-diagnosed cardiovascular diseases, had kidney or liver failure, and had the chronic obstructive pulmonary disease were not included in the study.

Primary outcomes:
measure: From the first measurement, 2 more measurements were taken, 28 days apart, and a total of 3 blood measurements were taken from the participants. Antibody levels were measured with the fluorescent immunological (FIA) method.
timeFrame: Within research completion, an average of 8 week
Secondary outcomes:
measure: From the first measurement, 2 more measurements were taken, 28 days apart, and a total of 3 blood measurements were taken from the participants. 25(OH) Vitamin D level levels were measured with the fluorescent immunological (FIA) method.
timeFrame: Within research completion, an average of 8 week
Other outcomes:
Locations:
city: Trabzon
country: Turkey
facility: Avrasya University
Study officials:
References:
Clinical trial NCT00555165: A Study of an Implantable Miniature Telescope in Patients With With End-Stage AMD
Official title: A Prospective Multicenter Clinical Study of the Implantable Miniature Telescope* in Patients With Central Vision Impairment Associated With AMD: IMT-UK Protocol (*IMT by Dr. Isaac Lipshitz)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: End Stage Macular Degeneration
Keywords: Macular Degeneration
Visual Impairment
Quality of Life
Implantable Telescope
Lead sponsor: VisionCare, Inc.
Sponsor class: INDUSTRY
First posted: 2007-11-07
Enrollment: 18
Sex: ALL
Minimum age (years): 55
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Evaluation of pre and post-implantation management of patients with end-stage age-related macular degeneration (AMD) who have been implanted with the implantable telescope (IMT) under CE Mark indicated use. This study is designed to evaluate in particular the optimal parameters for patient selection for use of this device in routine clinical practice.


Eligibility criteria: Inclusion Criteria:

CE Mark approved indication of use which includes

* At least 55 years of age
* Bilateral visual impairment due to geographic atrophy or disciform scars
* Evidence of cataract

Exclusion Criteria:

* Active CNV (or 'wet' AMD)
* Prior cataract or refractive surgery in the study eye

Primary outcomes:
measure: Best-Corrected Visual Acuity
timeFrame: 1 year
Secondary outcomes:
measure: Quality of Life
timeFrame: 1 year
Other outcomes:
Locations:
city: Frimley
country: United Kingdom
facility: Frimley Park Hospital NHS Trust
state: Surrey
city: Belfast
country: United Kingdom
facility: Royal Hospitals, Belfast Health & Social Care Trust
city: London
country: United Kingdom
facility: Moorfields Eye Hospital NHS Trust
city: London
country: United Kingdom
facility: King's College Hospital NHS Trust
Study officials:
affiliation: Royal Hospitals, Belfast Health & Social Care Trust
name: Giuliana Silvestri, MD FRCP FRCS
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05755165: Adolescent Depression: Video Ads on Instagram
Official title: Reducing Depression-related Stigma and Increasing Help-seeking Intentions: a Randomized Trial of Video Ads on Instagram
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Depression
Stigmatization
Lead sponsor: Yale University
Sponsor class: OTHER
First posted: 2023-03-06
Enrollment: 1235
Sex: ALL
Minimum age (years): 14
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purposes of this study are to test among adolescent viewers the utility of different types of selfie short video-based messaging to:

1. Reduce stigma and self-stigma related to depression, and
2. Increase treatment-seeking intentions.

Detailed description: Intervention videos will each be self-recorded videos (of \~90-second duration) featuring the same underage professional (ages 16) acting as simulated participant. The investigators will post three brief videos ('video Ads') to achieve similar exposure among Instagram users, 14-18-year-old. The videos are: (a) depression video; (b) depression video adjusted to race experiences, and (c) control videos. All videos will feature by the same Black adolescent girl.

The investigators intend to assign \~10,000 individuals aged 14-18 in a randomized way, in equal proportions, and stratified by sex and race, to view one of the three videos.

Outcomes will include:

1. Primary outcome: engagement (a composite of likes, shares, comments, and views)
2. Secondary outcome: clicks on a designated link at the end of the video ad.

Eligibility criteria: Inclusion Criteria:

* English-speaking
* Living in the US
* Ages 14 - 18

Exclusion Criteria:

* None

Primary outcomes:
measure: Engagement composite
timeFrame: Day 1: within 10 minutes of viewing the ad
Secondary outcomes:
measure: Clicks on designated link
timeFrame: Day 1: within 10 minutes of viewing the ad
Other outcomes:
Locations:
city: New Haven
country: United States
facility: Yale Child Center
state: Connecticut
city: New Haven
country: United States
facility: Yale Child Study Center
state: Connecticut
Study officials:
References:
citation: Martin A, Calhoun A, Paez J, Amsalem D. Destigmatizing perceptions about Black adolescent depression: randomized controlled trial of brief social contact-based video interventions. J Child Psychol Psychiatry. 2022 Nov;63(11):1270-1278. doi: 10.1111/jcpp.13570. Epub 2022 Jan 23.
citation: Amsalem D, Martin A. Reducing depression-related stigma and increasing treatment seeking among adolescents: randomized controlled trial of a brief video intervention. J Child Psychol Psychiatry. 2022 Feb;63(2):210-217. doi: 10.1111/jcpp.13427. Epub 2021 Apr 6.
citation: Amsalem D, Halloran J, Penque B, Celentano J, Martin A. Effect of a Brief Social Contact Video on Transphobia and Depression-Related Stigma Among Adolescents: A Randomized Clinical Trial. JAMA Netw Open. 2022 Feb 1;5(2):e220376. doi: 10.1001/jamanetworkopen.2022.0376.
Clinical trial NCT00284765: Management of the Sprained Ankle by Help of NSAID-Plaster
Official title: Optimation of Treatment of the Sprained Ankle by Help of NSAID-Plaster (Flector). A Questionnaire.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: The Sprained Ankle
Lead sponsor: Kolding Sygehus
Sponsor class: OTHER
First posted: 2006-02-01
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: The purpose of this trial is to study the management of the sprained ankle by help of NSAID-plaster. A questionnaire. The effect of RICE and RICE + NSAID-plaster in the treatment of the sprained ankle, compared by pain-score.


Eligibility criteria: Inclusion Criteria:

* A sprained ankle, less than 24 hours old, understanding Danish, 18 years or older

Exclusion Criteria:

* Fracture of the ankle, wound around the ankle, allergy of NSAID- pregnancy, daily use of NSAID, GI-bleeding

Primary outcomes:
measure: Pain-score
Secondary outcomes:
Other outcomes:
Locations:
city: Kolding
country: Denmark
facility: Kolding Sygehus
Study officials:
affiliation: Kolding Sygehus
name: Berit Jørgensen, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04955665: Reattachment of the SPR Versus the Bone Block Procedure for Recurrent Peroneal Tendon Dislocation
Official title: The Clinical Efficacy of Reattachment of the Superior Peroneal Retinaculum Versus the Bone Block Procedure for Recurrent Peroneal Tendon Dislocation
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Recurrent Peroneal Tendon Dislocation
Lead sponsor: Peking University Third Hospital
Sponsor class: OTHER
First posted: 2021-07-09
Enrollment: 47
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: A consecutive series of patients with recurrent peroneal tendon dislocation who underwent operative treatment between 2012 and 2016 were retrieved. Twenty-five patients underwent bone block procedure (group A), and 22 patients underwent reattachment of the SPR (group B)."

Brief summary: Clinical outcomes between reattachment of the superior peroneal retinaculum (SPR) and the bone block procedure were compared in this study to elucidate which procedure was safer and more effective.

Detailed description: From 2012 to 2016, 25 patients with recurrent peroneal tendon dislocation underwent the bone block procedure(group A), and another 22 patients underwent reattachment of the SPR (group B). American Orthopaedic Foot and Ankle society (AOFAS) ankle-hindfoot score, Ankle Activity Score (AAS), time to return to sports activity, rate of return to sports level, range of motion (ROM) of the ankle, rate of recurrence, and overall patient satisfaction were collected to evaluate outcomes between the two groups.

Eligibility criteria: Inclusion Criteria:

* a traumatic recurrent peroneal tendon dislocation requiring surgery
* a lack of response to at least 3 months of conservative treatment

Exclusion Criteria:

* the presence of an acute peroneal tendon dislocation
* a concomitant anterior talofibular ligament rupture

Primary outcomes:
measure: AOFAS
timeFrame: 2 years after operation
Secondary outcomes:
measure: VAS
timeFrame: 2 years after operation
measure: time to return to sports activity
timeFrame: up to 2 years
Other outcomes:
Locations:
Study officials:
affiliation: Peking University Third Hospital
name: Qinwei Guo, MD
role: STUDY_CHAIR
References:
Clinical trial NCT00663065: A Study of the Safety of PAZ-417 in Healthy Elderly Adults
Official title: An Ascending Multiple-Dose Study of the Safety, Pharmacokinetics, and Pharmacodynamics of PAZ-417 Administered Orally to Elderly Subjects
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Healthy
Keywords: Healthy subjects over 65
healthy subjects
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
Sponsor class: INDUSTRY
First posted: 2008-04-21
Enrollment: 40
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is study to determine the safety of PAZ-417 in healthy adults over 65.


Eligibility criteria: Inclusion:

1. A signed and dated IRB-approved informed consent form before any study specific screening procedures are performed.
2. Ability to read English or Spanish.
3. Men or women greater than or equal to 65 years of age on study day 1. Women must be either surgically sterile (hysterectomy and/or oophorectomy) or postmenopausal for greater than or equal to 1 year (with estradiol less than or equal to 25 pg/mL\[92 pmol/L\] and FSH greather than or equal to 38 mIU/mL) and must have a negative serum pregnancy test result within 48 hours before administration of test article. Women who are surgically sterile must provide documentation of the procedure by an operative report or by ultrasound.
4. Subjects should have a hemoglobin level greater than or equal to 12 g/dL at the screening visit.

Exclusion

1. Any significant unstable or uncontrolled cardiovascular, hepatic, renal, respiratory, gastrointestinal, endocrine, immunologic, dermatologic, hematologic, neurologic, or psychiatric disease.
2. History of vascular disorders (peripheral, coronary, venous), chronic inflammatory disorders (eg, rheumatoid arthritis), hematologic disorders, or bleeding disorders (eg, hemophilia, idiopathic thrombocytopenic purpura, VonWillebrand disease).
3. Presence or history of symptomatic vertigo, significant cardiac valvular disease, congestive heart failure, angina pectoris significant cardiac arrhythmia, or seizures.

Primary outcomes:
measure: safety as determined by adverse events, ECGs, vitals signs, and laboratory test results
timeFrame: 6 months
Secondary outcomes:
measure: Drug distribution in the blood
timeFrame: 6 months
Other outcomes:
Locations:
city: Tempe
country: United States
state: Arizona
Study officials:
affiliation: Wyeth is now a wholly owned subsidiary of Pfizer
name: Medical Monitor
role: STUDY_DIRECTOR
References:
Clinical trial NCT05749965: Results of Unicompartmental Knee Arthroplasties in Patients Beyond Historical Indications (PUCIL)
Official title: Unicompartimental Knee Arthroplasties When Borders Are Crossed : Survival Study at 7 Years
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Knee Disease
Lead sponsor: Central Hospital, Nancy, France
Sponsor class: OTHER
First posted: 2023-03-01
Enrollment: 522
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All medial UKA implanted between 2009 and 2015 at the CCEG with follow up at 7 years

Brief summary: Primary objective:

To compare medial uni compartimental knee arthroplasty between patients who had a limit factor prior to the surgery ans patients who fill thé historical criteria.

Secondary objectives

1 to compare survival of medial UKA between patients with one limit factor and those with multiple limits.

2. To identify the prognosis factors of failure in medial UKA in our center during the time of our analysis (2009-2015)

Detailed description: 7 year follow up survival if no amputation or no removal of UKA for TKA

Eligibility criteria: Inclusion Criteria:

- medial UKA implanted between 2009 and 2015 at the CCEG

Exclusion Criteria:

* no other UKA
* lost to follow up
* patient refuses

Primary outcomes:
measure: Survival of medial UKA
timeFrame: 7 years
Secondary outcomes:
measure: to compare UKA survival if multiple limit indication
timeFrame: 7 years
measure: to identify prognostic factors of re operation of patients with a medial UKA implanted between 2009 and 2015 at the CCEG
timeFrame: 7 years
Other outcomes:
Locations:
city: Nancy
country: France
facility: Centre Chirurgical Emile Gallé
Study officials:
affiliation: Central Hospital, Nancy, France
name: Andre Fernandez
role: STUDY_DIRECTOR
References: